BioNexus Gene Lab Corp Common stock (BGLC) — Capital Reinvestment Ratio
BioNexus Gene Lab Corp Common stock (BGLC) has a Capital Reinvestment Ratio of 0.04x as of December 2022, meaning it reinvests 0% of its operating cash flow ($474.47K) in capital expenditures ($17.03K). Check how tangible is BioNexus Gene Lab Corp Common stock's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BioNexus Gene Lab Corp Common stock Capital Reinvestment Ratio (2017–2022)
This chart tracks BioNexus Gene Lab Corp Common stock's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see BioNexus Gene Lab Corp Common stock (BGLC) cash conversion ratio.
Annual Capital Reinvestment Ratio for BioNexus Gene Lab Corp Common stock (2017–2022)
Year-by-year Capital Reinvestment Ratio for BioNexus Gene Lab Corp Common stock from 2017 to 2022. See BGLC free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.10x | $544.03K | $54.17K | ▼ -71.2% |
| 2021 | 0.35x | $9.16K | $3.16K | ▼ -54.8% |
| 2020 | 0.76x | $552.68K | $421.62K | ▼ -13.4% |
| 2017 | 0.88x | $357.22K | $314.82K | — |